Payment overview · 2025
General Payments
$418.50
21 reported records · 10 companies
Healthcare provider profile · identity verified
Hal Bradley Ganzman, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1285794545
Verified facts
What the public records show
CMS Open Payments records show Hal Bradley Ganzman, D.O. received $418.50 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.69 | 30.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.20 | 14.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.05 | 11.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.66 | 9.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.65 | 8.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.79 | 6.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.39 | 6.3% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.21 | 5.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.76 | 4.5% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $17.10 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $418.50 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.20 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.20 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.20 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.39 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 91 |
| Metformin Hcl | Metformin Hcl | 249 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 61 |
| Simvastatin | Simvastatin | 176 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 57 |
| Lisinopril | Lisinopril | 142 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 47 |
| Furosemide | Furosemide | 129 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 54 |
| Losartan Potassium | Losartan Potassium | 113 | 42 |
| Gabapentin | Gabapentin | 109 | 34 |
| Omeprazole | Omeprazole | 109 | 38 |
| Eliquis | Apixaban | 101 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 35 |
| Valsartan | Valsartan | 98 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 28 |
| Famotidine | Famotidine | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 39 |
| Sertraline Hcl | Sertraline Hcl | 68 | 18 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Atenolol | Atenolol | 67 | 20 |
| Alprazolam | Alprazolam | 66 | 25 |
| Montelukast Sodium | Montelukast Sodium | 64 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Prednisone | Prednisone | 61 | 49 |
| Lorazepam | Lorazepam | 56 | 23 |
| Benazepril Hcl | Benazepril Hcl | 54 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 16 |
| Allopurinol | Allopurinol | 48 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | 13 |
| Cefuroxime | Cefuroxime Axetil | 47 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Glipizide Er | Glipizide | 44 | 13 |
| Ozempic | Semaglutide | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 13 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Irbesartan | Irbesartan | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 15 |
| Carvedilol | Carvedilol | 35 | 14 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 23 |
| Potassium Chloride | Potassium Chloride | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 14 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 12 |
| Repaglinide | Repaglinide | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 11 |
| Lovastatin | Lovastatin | 26 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | 13 |
| Meloxicam | Meloxicam | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Etodolac | Etodolac | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Nadolol | Nadolol | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Ursodiol | Ursodiol | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $418.50 · 21 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, FARXIGA, GLYCATE, INSPIRE, MOUNJARO, Ozempic, RELTONE 200 MG, RELTONE 400 MG, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, WELLBUTRIN, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error